title: Modeling preventative strategies against human papillomavirus-related disease in developed countries.
abstract: Over the last 5 years, prophylactic vaccination against human papillomavirus (HPV) in pre-adolescent females has been introduced in most developed countries, supported by modeled evaluations that have almost universally found vaccination of pre-adolescent females to be cost-effective. Studies to date suggest that vaccination of pre-adolescent males may also be cost-effective at a cost per vaccinated individual of ~US$400-500 if vaccination coverage in females cannot be increased above ~50%; but if it is possible, increasing coverage in females appears to be a better return on investment. Comparative evaluation of the quadrivalent (HPV16,18,6,11) and bivalent (HPV16,18) vaccines centers around the potential trade-off between protection against anogenital warts and vaccine-specific levels of cross-protection against infections not targeted by the vaccines. Future evaluations will also need to consider the cost-effectiveness of a next generation nonavalent vaccine designed to protect against ~90% of cervical cancers. The timing of the effect of vaccination on cervical screening programs will be country-specific and will depend on vaccination catch-up age range and coverage and the age at which screening starts. Initial evaluations suggest that if screening remains unchanged, it will be less cost-effective in vaccinated compared to unvaccinated women but, in the context of current vaccines, will remain an important prevention method. Comprehensive evaluation of new approaches to screening will need to consider the population-level effects of vaccination over time. New screening strategies of particular interest include delaying the start age of screening, increasing the screening interval and switching to primary HPV screening. Future evaluations of screening will also need to focus on the effects of disparities in screening and vaccination uptake, the potential effects of vaccination on screening participation, and the effects of imperfect compliance with screening recommendations. This article forms part of a special supplement entitled "Comprehensive Control of HPV Infections and Related Diseases" Vaccine Volume 30, Supplement 5, 2012.
authors.affiliation: Cancer Epidemiology Research Unit, Cancer Council NSW, Sydney, Australia. karenc@nswcc.org.au
authors.forename: Karen
authors.initials: K
authors.lastname: Canfell
authors.forename: Harrell
authors.initials: H
authors.lastname: Chesson
authors.forename: Shalini L
authors.initials: SL
authors.lastname: Kulasingam
authors.forename: Johannes
authors.initials: J
authors.lastname: Berkhof
authors.forename: Mireia
authors.initials: M
authors.lastname: Diaz
authors.forename: Jane J
authors.initials: JJ
authors.lastname: Kim
mesh_terms: D003218:Condylomata Acuminata / Q000453:epidemiology / Q000517:prevention & control; D003362:Cost-Benefit Analysis; D019049:Developed Countries; D005260:Female; D005833:Genital Neoplasms, Female / Q000453:epidemiology / Q000517:prevention & control*; D005834:Genital Neoplasms, Male / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000191:economics / Q000379:methods; D030361:Papillomavirus Infections / Q000150:complications* / Q000453:epidemiology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage*; D014611:Vaccination / Q000191:economics / Q000706:statistics & numerical data; D014773:Virology / Q000191:economics / Q000379:methods
chemical_list: D053918:Papillomavirus Vaccines